Regenxbio shared positive data from the AFFINITY DUCHENNE trial of RGX-202. In addition to robust microdystrophin expression, Regenxbio reported functional benefits at 9 and 12 months after treatment for all of the first 5 participants receiving the pivotal dose (2E14 GC/kg), aged 6-12 years at dosing. You can learn more here and during a webinar [REGISTER HERE], CureDuchenne is hosting with Regenxbio on Wednesday, June 11th at 1 pm ET.
Read the Community Letter Below:
The post Regenxbio reports positive interim data from Phase 1/2 microdystrophin gene therapy trial appeared first on CureDuchenne.